The global predictive biomarkers market was valued at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.02% from 2025 to 2030. This significant growth is primarily driven by advancements in genomics and precision medicine, increased investment in research and development, and a rising demand for early detection and personalized treatments.

Key Market Trends & Insights

• Technological Advancements: The integration of next-generation sequencing (NGS) and artificial intelligence (AI) is revolutionizing biomarker discovery and validation processes. These technologies enable the identification of novel biomarkers and enhance the accuracy of predictive models, facilitating personalized treatment strategies.
• Rising Incidence of Chronic Diseases: The increasing prevalence of chronic conditions such as cancer, cardiovascular diseases, and neurological disorders is propelling the demand for predictive biomarkers. Early detection through predictive biomarkers allows for timely intervention, improving patient outcomes.
• Regulatory Support: Regulatory agencies are providing favorable guidelines and approvals for biomarker-based diagnostics, encouraging the development and adoption of predictive biomarkers in clinical settings.

Market Size & Forecast

The market is expected to continue its upward trajectory, with significant contributions from regions such as North America, Europe, and Asia-Pacific. North America is anticipated to maintain its dominance due to robust healthcare infrastructure and substantial investments in research and development. Asia-Pacific is projected to exhibit the highest growth rate, driven by increasing healthcare expenditures and a growing patient population.

Order a free sample PDF of the Predictive Biomarkers Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

Leading companies in the predictive biomarkers market include Illumina, Thermo Fisher Scientific, Roche, QIAGEN, and Bio-Rad Laboratories. These companies are focusing on strategic collaborations, product innovations, and expanding their portfolios to strengthen their market position. For instance, collaborations between AI firms and biotechnology companies are accelerating the development of advanced biomarker discovery platforms.

Key Companies List

• Illumina: A leader in NGS technology, Illumina offers comprehensive solutions for genomic analysis, facilitating the identification of predictive biomarkers.
• Thermo Fisher Scientific: Provides a wide range of analytical instruments and reagents for biomarker discovery and validation.
• Roche: Engages in the development of companion diagnostics and personalized medicine approaches, integrating predictive biomarkers into clinical practice.
• QIAGEN: Specializes in molecular diagnostics and offers platforms for biomarker analysis, supporting personalized treatment strategies.
• Bio-Rad Laboratories: Offers a variety of tools and reagents for biomarker research, contributing to advancements in predictive diagnostics.

Conclusion

The predictive biomarkers market is poised for substantial growth, driven by technological advancements, an increasing burden of chronic diseases, and supportive regulatory frameworks. As the demand for personalized medicine continues to rise, predictive biomarkers will play a pivotal role in transforming healthcare by enabling early detection and tailored treatment strategies. Stakeholders in the healthcare industry must focus on innovation and collaboration to harness the full potential of predictive biomarkers and improve patient outcomes.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.